News | November 08, 2023
Evonik launches GMP-quality plant-based squalene
PhytoSquene now available for clinical and commercial use
PhytoSquene now available for clinical and commercial use
The newly developed adhesive is available in two different grades. Loctite WT 3001 and Loctite WT 3003 h
In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026
Aster Whitefield will be Aster's 3 rd multi-specialty hospital in Bengaluru and overall 19th hospital in India
The initiative will focus on advocating for cleaner air
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines
The companies plan to start a pivotal Phase 3 trial in the coming months
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
Subscribe To Our Newsletter & Stay Updated
